Certified by Founder Lodge
Switch Therapeutics
United States - San Francisco, California
START UP
1 Disclosed Funding Rounds $52,000,000
0 Participating Investments
-
Founded date
2020
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science wi
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| March, 15 ,2023 | Series A | $52,000,000 |
Dolby Family Ventures
Upfront Ventures
BOLD Capital Partners
Eli Lilly and Company
Digitalis Ventures
FreeFlow Ventures
UCB Ventures
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
StretchSense | $2,300,000 | (Dec 23, 2025)
Ciphero | $2,500,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
